Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies. “Liselotte is one of few persons in Sweden who possess such extensive competence in quality management […]
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
Xintela AB (publ) announces that the company is a partner in a project, financed by Vinnova and Vetenskapsrådet, to establish an international research center for effective production and development of Advanced Therapy Medicinal Products in cell and gene therapy. The project has been granted 48 MSEK in financing and will have a duration of six […]
Xintela signs memorandum of understanding with CO.DON
Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela’s quality markers for CO.DON’s next cell-based product and for the co- development of Xintela’s stem cell product for the treatment of osteoarthritis. […]
Keld Søndergaard nominated as new board member
The Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for election as a new member of the Board at the annual general meeting on the 18th of May 2017. Also proposed for re-election are Greg Batcheller, Karin Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders who represent […]
Xintela strengthens business development and reorganizes
Xintela announces today that Thomas Areschoug has been recruited to the business development team as Business Development Manager. In addition, the company is reorganizing in order to develop its projects more efficiently. – We are very pleased to have Thomas Areschoug join the team. His broad international network and experience is exactly what Xintela now […]
Xintela reports positive preclinical results in cancer project
Xintela AB (publ) today announces an update of the company’s projects in regenerative medicine and cancer. All projects are developing in a positive way. New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model. Significant progress in the treatment of the brain […]
Xintela’s stem cells show positive treatment effects on cartilage damage in horse study
Xintela AB (publ), announces today that the company’s selected stem cells have beneficial effects on joint cartilage and underlying bone in post- traumatic osteoarthritis, based on additional analysis of the company’s horse study and the final report from Cornell University, Ithaca, New York. The results are very promising for Xintela’s development of stem cell therapy […]
Xintela reports positive results from completed horse study
Xintela AB (publ), announces today that the company’s completed horse study met its primary endpoint, demonstrating that Xintela’s stem cells are safe. Xintela can now take the next step in the development of an effective, safe stem cell product for the treatment of cartilage damage and osteoarthritis. “We are very pleased to report a positive […]
Xintela’s Focus in the Cancer Arena
XINMARK is Xintela’s patented integrin technology platform that is being developed with the aim of commercialising innovative and improved treatments in two main areas: regenerative medicine and cancer. Within the cancer arena, Xintela’s research focuses on glioblastoma, an aggressive brain tumour, and this newsletter provides an update on our progress to date.
Focus on commercial development
As our projects progress, it is important to ensure that we have the right competencies to take them towards commercialisation. We are therefore delighted to start the Autumn with two new employees who will strengthen the company’s commercial team. Lina Boreson, with extensive experience from the pharmaceutical industry as, amongst other roles, Head of Marketing, […]
